Introduction
�������� ���� ��������� ��CC� �� � ��������� ������ ��d �f��� ������ �� �������� �p��h����, �����d��� �h� ���� �����y, esophagus, uterine cervix, anal canal and skin. In 1977, Kato and Torigoe, first discovered the squamous cell carcinoma ������� ��CCA� �� � �������� ���� ��������� �f �h� ������� �����x �1�. �CCA �� � ��w ���b�� �f �h� ������ p������� ��h�b�-���� ����p���� f����y �2�. �CCA ���� ����� �������� �CCA1 ����p��B3� ��d �CCA2 ����p��B4� �����, wh��h ����d� �h� ������� ��d ���d�� f���� �f �h� p������, ���p�������y. Th� ������� �CCA1 �� ��������y p������ ����d� b��h ������ ��d ��������� �����, wh����� ���d�� �CCA2 �� �����y �������d by ��������� ����� ��d �� �f��� �������d �� p������� w��h �CC� �3,4�. M��y ���d��� h��� �h�w� �h�� �������d ����� �CCA ������, �����d��� �CCA1 ��d �CCA2, ��� f���d �� p������� w��h �CC �f �����x, h��d ��d ���k, ���ph���� ��d ���� �5-8�. Add��������y, h��h �CCA �������������� w��� f���d �� ������ ������ ��d �� ���������� �y�ph ��d��, wh��� �������� �������� �y�ph ��d�� from the same patients presented significantly less SCCAs (9) . A� p������, �������� d��� ��pp��� �h� �����p� �h�� �CCA� ��� SCC-specific tumor antigens and that elevated serum SCCA ������ ��������� w��� w��h �h� �x���� �f d������ �� p������� w��h �CC�. Th���f���, ����y� f�� �CCA� ��� w�d��y ���d f�� �h� d�������� ��d ���������� �f p������� w��h �CC �f �h� ������� �����x ��d ��h�� ������ �10,11�.
M��y in vitro ��d in vivo ���d��� h��� ��������d �� ��p������ ���� �f �CCA� �� �h� ��d������� �f p��������d ���� d���h ��d �h� p�������� �f ����� T-cell induction assay. C57BL/6-Transgenic (HLA-A2.1) 1Enge/J mice (HLA-A*0201 transgenic mice) were purchased f��� �h� J��k��� L�b������y �B�� H��b��, ME, U�A� ��d b��d under specific pathogen free conditions. MHC-peptide complex stabilization assay. Th� b��d��� affinity of peptides to the HLA-A*0201 molecule was deter����d �����������������y by d�������� �h� �p���������� �f peptide-inducing HLA-A*0201 molecules on T2 cells by flow �y������y. Th� HLA-A*0201-p�p��d� ���p��x ���b���z����� assay was performed as previously described (27) . Briefly, T2 ����� �1x10 5 /well) were incubated with individual peptides �� d�ff����� �������������� �1, 10 �� 100 µM� �� 24-w��� plates for 1 h at 37˚C, 18 h at 28˚C, followed by 3 h at 37˚C. T2 ����� w��h��� p�p��d� �����d �� b��k�����d �������. Af��� incubation, the T2 cells were incubated with FITC-conjugated anti-HLA-A*0201 mAb (BD Pharmingen, San Diego, CA, USA) for 40 min at 4˚C. Cells were washed two times with PB� ��d ����yz�d ����� � FAC�C���b�� f��w �y������� (BD Biosciences, CA, USA). The mean fluorescence index �MFI� w�� �����d�d, ��d �h� f����������� ��d�x �FI� w�� ���������d ����� �h� f����w��� f������. FI>1 �100 µM p�p��d�� indicated that the tested peptide had a high affinity for the HLA-A*0201 ��������.
In vitro generation of peptide-specific CD8 + T cells. Th� in vitro CD8
+ T-���� ��d������ ����y w�� p��f����d �� p����-����y d�����b�d �25�. B���f�y, 8x10 6 HLA-A*0201-p������� PBMC� w��� �������d �� RPMI-1640 ��d��� ��pp�������d with 10% FBS, 100 U/ml penicillin, 100 µM streptomycin, given peptide (50 µM) 100 U/ml recombinant interleukin 2 �P�p�����h I��, R��ky H���, NJ, U�A�. E���y 3 �� 4 d�y�, h��f �f �h� ������� ��d��� w�� ������d ��d ��p����d w��h f���h RPMI-1640 medium. On the 28th day (1 week after the final ������������, �h� p�p��d�-���������d PBMC� ��ff����� ������ were tested for peptide-specific CD8 + IFN-γ + T ����� ��d �h� �b����y �� �y�� p�p��d�-p����d T2 �����.
Immunization of HLA-A*0201 transgenic mice. HLA-A*0201 ���������� ���� �6-8 w��k� �f ���� w��� ��bd���d�d ���� ���h� groups (5 mice/group). Peptide (250 µg) and 250 µg PADRE in 500 µl PBS were emulsified in 500 µl Complete Freund's Adjuvant (CFA). Subsequently, 1 ml of the mixture was injected subcutaneously (s.c.) into the back skin and the tail base of transgenic mice (50 µg given peptide/mouse). After 1 w��k, �h� ��x����, 250 µ� �f �h� ���� p�p��d� �� 250 µ� PBS and 250 µl Incomplete Freund's Adjuvant (IFA), were ���d �� b���� ���� ���� � w��k f�� 4 w��k�. C������ ���� ����k-������z�d ����� �������d CFA ��d IFA b�� w��h��� peptide. One week after the final immunization, the spleen, �y�ph ��d�� �d����p������� ��d p�p������ �y�ph ��d���, ��d EDTA-treated blood were harvested and prepared for single ���� ���p�������. Th� �p�����y��� w��� ���d f�� ELI�POT ����y, IC� ����y ��d in vitro �y����x����y ����y. Ly�ph ��d� ����� ��d PBMC� w��� ���d f�� ELI�POT ����y. Th� p�������� f�� �h� ������ �xp�������� �� �h�� ���dy w��� �pp����d by �h� A����� E�h��� C�������� �f W��zh�� M�d���� C������. 
IFN-γ ELISPOT assay. P�������d ������ IFN-γ ELI�POT
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